Financial insights of BIXT

MyFinsight

For the quarter ending 2025-09-30.

Income Statement	2025-09-30	2025-06-30
Research and development	-	102,500
General and administrative	159,131	99,531
General and administrative affiliates	336,874	22,048
Total operating expenses	496,005	224,079
Loss from operations	-496,005	-224,079
Change in fair value (fv) of derivative	264,796	307,402
Interest expense	36,522	30,112
Interest expense affiliates	10,759	15,265
Gain/loss of issuance	-	0
Debt discount amortization and issuance of warrants	-	0
Amortization of ip	4,236	2,509
Total other income (expenses)	213,279	259,516
Net loss before provision for income taxes	-282,726	35,437
Provision for income taxes	-	0
Net loss	-282,726	35,437
Net loss attributable to the non-controlling interest	-	0
Net loss attributable to bioxytran	-282,726	35,437

Basic EPS	0	0
Diluted EPS	0	0
Basic Average Shares	88,992,242	88,839,723
Diluted Average Shares	88,992,242	88,839,723

Unit: Dollar. Numbers labeled with * are estimated quarterly values.